Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.

NCT01996319 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

194

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: QVA149
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals